Lars Wallentin
A5063591215- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Coronary Interventions and Diagnostics
- Cardiac Arrhythmias and Treatments
- Lipoproteins and Cardiovascular Health
- Cardiac electrophysiology and arrhythmias
- Heart Failure Treatment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Function and Risk Factors
- GDF15 and Related Biomarkers
- Acute Ischemic Stroke Management
- Blood Pressure and Hypertension Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac Health and Mental Health
- Estrogen and related hormone effects
- Adipokines, Inflammation, and Metabolic Diseases
- Diabetes Treatment and Management
- Hormonal and reproductive studies
- Nutrition and Health in Aging
- Cardiac Fibrosis and Remodeling
- Genetic Associations and Epidemiology
Uppsala University
2016-2025
Uppsala University Hospital
2012-2024
European Society of Cardiology
2020-2024
Thrombolysis in Myocardial Infarction Study Group
2011-2024
Brigham and Women's Hospital
2002-2024
Harvard University
2009-2024
Associazione Nazionale Medici Cardiologi Ospedalieri
2019-2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2024
New York University
2024
Duke University
2002-2022
Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases hemorrhage and is difficult to use. Dabigatran a new oral direct thrombin inhibitor.
Vitamin K antagonists are highly effective in preventing stroke patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of similar population comparison aspirin.In this randomized, double-blind trial, we compared apixaban (at dose 5 mg twice daily) warfarin (target international normalized ratio, 2.0 3.0) 18,201 and at least one additional for stroke. The primary outcome was ischemic or...
Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and pronounced platelet inhibition than clopidogrel.In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) clopidogrel (300-to-600-mg 75 for prevention cardiovascular events in 18,624 patients admitted to hospital with acute coronary syndrome, or without ST-segment elevation.At 12 months,...
![Graphic][1] Myocardial infarction is a major cause of death and disability worldwide. Coronary atherosclerosis chronic disease with stable unstable periods. During periods activated inflammation in the vascular wall, patients may develop myocardial infarction. Myocardial be minor event lifelong disease, it even go undetected, but also catastrophic leading to sudden or severe haemodynamic deterioration. A first manifestation coronary artery occur, repeatedly, established disease....
Guidelines and Expert Consensus Documents summarize evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting best management strategies for typical patient, suffering from given condition, taking into account impact outcome, as well risk–benefit ratio of diagnostic or therapeutic means. are no substitutes textbooks. The legal implications medical guidelines have been discussed previously. A great number issued recent years by European...
In patients with unstable coronary artery disease, there is a relation between the short-term risk of death and blood levels troponin T (a marker myocardial damage) C-reactive protein fibrinogen (markers inflammation). Using information obtained during an extension follow-up period in Fragmin Instability Coronary Artery Disease trial, we evaluated usefulness T, protein, other indicators as predictors long-term from cardiac causes.
Recent reports have indicated that there may be an increased risk of late stent thrombosis with the use drug-eluting stents, as compared bare-metal stents.We evaluated 6033 patients treated stents and 13,738 in 2003 2004, using data from Swedish Coronary Angiography Angioplasty Registry. The outcome analysis covering a period up to 3 years was based on 1424 deaths 2463 myocardial infarctions adjusted for differences baseline characteristics.The two study groups did not differ significantly...
Background— Dabigatran 150 and 110 mg twice a day warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks bleeding the Randomized Evaluation Long-Term Anticoagulant Therapy (RE-LY) trial. Methods Results— RE-LY trial randomized 18 113 patients receive dabigatran or dose adjusted an international normalized ratio 2.0 3.0 median follow-up years. Compared with warfarin, associated lower risk major (2.87% versus 3.57%; P =0.002),...
Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after acute coronary syndrome.We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at dose 5 mg twice daily, with placebo, in addition standard therapy, patients recent syndrome and least two additional factors for events.The was terminated prematurely recruitment 7392 because increase major bleeding apixaban absence...
ContextDespite many therapeutic advances, mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) remains high. The role of additional antithrombotic agents is unclear, especially among not receiving reperfusion therapy.ObjectiveTo evaluate the effect fondaparinux, a factor Xa inhibitor, when initiated early and given for up to 8 days vs usual care (placebo those whom unfractionated heparin [UFH] indicated [stratum 1] or 48 hours followed by placebo 2])...
The full text of this document is available on the Website European Society Cardiology: www.escardio.org in section ‘Scientific Information’, Guidelines. Introduction 1809 Pathophysiology 1810 Plaque rupture and erosion Inflammation 1812 Thrombosis Vasoconstriction Myocardium 1813 Diagnosis Clinical presentation Physical examination Electrocardiogram Biochemical markers myocardial damage 1814 Recommendations 1815 Risk assessment factors 1816 Markers inflammatory activity thrombosis 1817...
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...